Study Supports Safety of POMELLA®

NOBELSVILLE, Ind.—A new study evaluating the safety of POMELLA® Extract has been accepted in peer review by the journal Food and Chemical Toxicology.
The study concluded the no-observed-adverse-effect level (NOAEL) of POMELLA was 600 mg/kg/day—the highest dose tested—which is exponentially higher than the recommended daily dosage of POMELLA. The study tested several doses of the clinically researched, punicalagins-standardized pomegranate extract over a 90-day period.
“As one of the first systematic safety studies performed on a commercial pomegranate extract, this study breaks new ground in our long-term commitment to ensure the safety and efficacy of our products,” said Blake Ebersole, technical director of Verdure Sciences.

www.pomextract.com